NASDAQ:HRTX - Heron Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$38.10 +0.15 (+0.40 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$38.10
Today's Range$37.05 - $38.45
52-Week Range$14.40 - $42.90
Volume457,140 shs
Average Volume1.22 million shs
Market Capitalization$3.01 billion
P/E Ratio10.44
Dividend YieldN/A
Beta1.56
Heron Therapeutics logoHeron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, a neurokinin-1 receptor antagonist aprepitant for the prevention of CINV; and HTX-011, which is in Phase III clinical development for the prevention of post-operative pain. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Receive HRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HRTX
CUSIPN/A
Phone858-251-4400

Debt

Debt-to-Equity RatioN/A
Current Ratio6.39
Quick Ratio6.04

Price-To-Earnings

Trailing P/E Ratio10.44
Forward P/E Ratio-17.40
P/E GrowthN/A

Sales & Book Value

Annual Sales$30.77 million
Price / Sales96.25
Cash Flow$3.0407 per share
Price / Cash12.53
Book Value$2.03 per share
Price / Book18.77

Profitability

EPS (Most Recent Fiscal Year)$3.65
Net Income$-197,480,000.00
Net Margins-411.41%
Return on Equity-112.35%
Return on Assets-74.65%

Miscellaneous

Employees145
Outstanding Shares77,730,000
Market Cap$3.01 billion

Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics Inc (NASDAQ:HRTX) released its quarterly earnings data on Wednesday, August, 8th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.14. The biotechnology company had revenue of $17.28 million for the quarter, compared to analysts' expectations of $12.82 million. Heron Therapeutics had a negative return on equity of 112.35% and a negative net margin of 411.41%. The firm's quarterly revenue was up 103.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.80) EPS. View Heron Therapeutics' Earnings History.

When is Heron Therapeutics' next earnings date?

Heron Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 5th 2018. View Earnings Estimates for Heron Therapeutics.

What price target have analysts set for HRTX?

10 analysts have issued twelve-month price objectives for Heron Therapeutics' stock. Their forecasts range from $24.00 to $80.00. On average, they anticipate Heron Therapeutics' share price to reach $50.80 in the next year. This suggests a possible upside of 33.3% from the stock's current price. View Analyst Price Targets for Heron Therapeutics.

What is the consensus analysts' recommendation for Heron Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heron Therapeutics.

What are Wall Street analysts saying about Heron Therapeutics stock?

Here are some recent quotes from research analysts about Heron Therapeutics stock:
  • 1. Cantor Fitzgerald analysts commented, ". Post a strong 2Q18, we are transferring coverage of HRTX and reiterating an Overweight rating and 12-month PT of $50. HRTX has successfully advanced HTX-011 towards a filing in the second half of this year, and we believe HTX-011’s uptake and peak sales potential could exceed Street estimates and our own. We expect upward earnings revisions, along with an approval of HTX-011, to drive HRTX shares higher. We expect upside to come from Cinvanti and HTX-011. Additionally, we believe that HRTX’s decision to retain global rights to HTX-011 could make HRTX an attractive addition to a larger company’s portfolio, or provide further upside to HRTX revenue estimates." (8/8/2018)
  • 2. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (7/18/2018)
  • 3. Mizuho analysts commented, "We expect HTX-011 to receive broad label and we see potential for a quicker review process by the FDA for a mid-2019 approval. We reiterate our Buy rating and raise our PT to $41." (6/22/2018)
  • 4. Cowen Inc analysts commented, "We are still waiting to speak with the company and have thus not yet updated our model and price target, but do not recommend buying on weakness." (3/19/2018)

Who are some of Heron Therapeutics' key competitors?

Who are Heron Therapeutics' key executives?

Heron Therapeutics' management team includes the folowing people:
  • Dr. Barry D. Quart, CEO & Director (Age 61)
  • Mr. Robert H. Rosen, Pres & Director (Age 62)
  • Mr. Robert E. Hoffman CPA, CFO & Sr. VP of Fin. (Age 52)
  • Ms. Kimberly J. Manhard, Exec. VP of Drug Devel. (Age 58)
  • Mr. David L. Szekeres, Sr. VP of Bus. Devel., Gen. Counsel & Corp. Sec. (Age 44)

Has Heron Therapeutics been receiving favorable news coverage?

News coverage about HRTX stock has trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Heron Therapeutics earned a media and rumor sentiment score of 0.11 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 47.20 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Heron Therapeutics.

Who are Heron Therapeutics' major shareholders?

Heron Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.69%), Janus Henderson Group PLC (8.16%), BlackRock Inc. (6.32%), Eagle Asset Management Inc. (2.44%), Orbimed Advisors LLC (1.69%) and Highland Capital Management LP (1.16%). Company insiders that own Heron Therapeutics stock include Barry D Quart, Kevin C Tang, Kimberly Manhard, Robert Hoffman and Robert Rosen. View Institutional Ownership Trends for Heron Therapeutics.

Which major investors are selling Heron Therapeutics stock?

HRTX stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Highland Capital Management LP, Stelliam Investment Management LP, EAM Investors LLC, Tavio Capital LLC, Eagle Asset Management Inc., EAM Global Investors LLC and Alps Advisors Inc.. Company insiders that have sold Heron Therapeutics company stock in the last year include Barry D Quart, Kimberly Manhard, Robert Hoffman and Robert Rosen. View Insider Buying and Selling for Heron Therapeutics.

Which major investors are buying Heron Therapeutics stock?

HRTX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Renaissance Technologies LLC, First Light Asset Management LLC, Jennison Associates LLC, Wells Fargo & Company MN, Millennium Management LLC and Orbimed Advisors LLC. View Insider Buying and Selling for Heron Therapeutics.

How do I buy shares of Heron Therapeutics?

Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Heron Therapeutics' stock price today?

One share of HRTX stock can currently be purchased for approximately $38.10.

How big of a company is Heron Therapeutics?

Heron Therapeutics has a market capitalization of $3.01 billion and generates $30.77 million in revenue each year. The biotechnology company earns $-197,480,000.00 in net income (profit) each year or $3.65 on an earnings per share basis. Heron Therapeutics employs 145 workers across the globe.

How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected]


MarketBeat Community Rating for Heron Therapeutics (NASDAQ HRTX)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  462 (Vote Outperform)
Underperform Votes:  220 (Vote Underperform)
Total Votes:  682
MarketBeat's community ratings are surveys of what our community members think about Heron Therapeutics and other stocks. Vote "Outperform" if you believe HRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.